| Reference |
|---|
Mei C, Zhang X, Zhi Y, Liang Z, Xu H, Liu Z, et al. Isorhamnetin Regulates Programmed Death Ligand-1 Expression by Suppressing the EGFR-STAT3 Signaling Pathway in Canine Mammary Tumors. Int J Mol Sci. 2024;25: pubmed publisher |
Wang S, Iyer R, Han X, Wei J, Li N, Cheng Y, et al. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion. J Clin Invest. 2023;133: pubmed publisher |
Mikitiuk M, Barczy x144 ski J, Bielski P, Arciniega M, Tyrcha U, Hec A, et al. IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins. Molecules. 2023;28: pubmed publisher |
Erlichman N, Meshel T, Baram T, Abu Raiya A, Horvitz T, Ben Yaakov H, et al. The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1. Cells. 2023;12: pubmed publisher |
Lellahi S, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, et al. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front Immunol. 2022;13:1058963 pubmed publisher |
Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, et al. NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. Int J Mol Sci. 2022;23: pubmed publisher |
Madhi H, Lee J, Choi Y, Li Y, Kim M, Choi Y, et al. FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation. Adv Sci (Weinh). 2022;9:e2202702 pubmed publisher |
Xu W, Liu W, Anwaier A, Tian X, Su J, Shi G, et al. Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma. Discov Oncol. 2022;13:59 pubmed publisher |
Bajor M, Graczyk Jarzynka A, Marhelava K, Burdzińska A, Muchowicz A, Góral A, et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022;10: pubmed publisher |
Ravindran Menon D, Li Y, Yamauchi T, Osborne D, Vaddi P, Wempe M, et al. EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals (Basel). 2021;14: pubmed publisher |
Lai C, Tseng P, Chen C, Satria R, Wang Y, Lin C. Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages. J Inflamm Res. 2021;14:5241-5249 pubmed publisher |
Mann J, Ludwig M, Kulkarni A, Scheftz E, Murray I, Zhai J, et al. Microbe-Mediated Activation of Toll-like Receptor 2 Drives PDL1 Expression in HNSCC. Cancers (Basel). 2021;13: pubmed publisher |
Bamodu O, Wang Y, Yeh C, Ho C, Chiang Y, Kao W, et al. Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer. Biomedicines. 2021;9: pubmed publisher |
Carbotti G, Dozin B, Martini S, Giordano C, Scordamaglia F, Croce M, et al. IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers (Basel). 2021;13: pubmed publisher |
Asano T, Boisson B, Onodi F, Matuozzo D, Moncada Velez M, Maglorius Renkilaraj M, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6: pubmed publisher |
Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536 pubmed publisher |
Castro Gutierrez R, Alkanani A, Mathews C, Michels A, Russ H. Protecting Stem Cell Derived Pancreatic Beta-Like Cells From Diabetogenic T Cell Recognition. Front Endocrinol (Lausanne). 2021;12:707881 pubmed publisher |
Spangenberg S, Zavareh R, Lairson L. Protocol for high-throughput compound screening using flow cytometry in THP-1 cells. STAR Protoc. 2021;2:100400 pubmed publisher |
Chen H, Li M, Ng N, Yu E, Bujarski S, Yin Z, et al. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br J Haematol. 2021;192:568-576 pubmed publisher |
Oulès B, Philippeos C, Segal J, Tihy M, Vietri Rudan M, Cujba A, et al. Contribution of GATA6 to homeostasis of the human upper pilosebaceous unit and acne pathogenesis. Nat Commun. 2020;11:5067 pubmed publisher |
Du L, Lee J, Jiang H, Wang C, Wang S, Zheng Z, et al. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 2020;217: pubmed publisher |
Heinz L, Lee J, Kapoor U, Kartnig F, Sedlyarov V, Papakostas K, et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 2020;581:316-322 pubmed publisher |
Cui B, Chen J, Luo M, Wang L, Chen H, Kang Y, et al. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling. Int J Oncol. 2020;56:909-920 pubmed publisher |
Neuwelt A, Kimball A, Johnson A, Arnold B, Bullock B, Kaspar R, et al. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8: pubmed publisher |
Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher |
Brodska B, Otevrelova P, Salek C, Fuchs O, Gasova Z, Kuzelova K. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. Int J Mol Sci. 2019;20: pubmed publisher |
Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua L, Koh V, et al. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer. Int J Oncol. 2019;54:2030-2038 pubmed publisher |
Xu L, Zhang Y, Tian K, Chen X, Zhang R, Mu X, et al. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res. 2018;37:261 pubmed publisher |
Dijkstra K, Cattaneo C, Weeber F, Chalabi M, van de Haar J, Fanchi L, et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174:1586-1598.e12 pubmed publisher |
Versteven M, Van den Bergh J, Broos K, Fujiki F, Campillo Davó D, De Reu H, et al. A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget. 2018;9:27797-27808 pubmed publisher |
Narasimhan P, Akabas L, Tariq S, Huda N, Bennuru S, Sabzevari H, et al. Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. PLoS Negl Trop Dis. 2018;12:e0006404 pubmed publisher |
Witt D, Donson A, Amani V, Moreira D, Sanford B, Hoffman L, et al. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer. 2018;65:e26960 pubmed publisher |
Dimitrov V, Bouttier M, Boukhaled G, Salehi Tabar R, Avramescu R, Memari B, et al. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem. 2017;292:20657-20668 pubmed publisher |
Baban B, Liu J, Qin X, Weintraub N, Mozaffari M. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS ONE. 2015;10:e0124059 pubmed publisher |
Wrangle J, Wang W, Koch A, Easwaran H, Mohammad H, Vendetti F, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013;4:2067-79 pubmed |
